VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
3.155
+0.025 (0.80%)
At close: Nov 7, 2024, 4:00 PM
3.110
-0.045 (-1.43%)
After-hours: Nov 7, 2024, 6:01 PM EST
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 2 or -16.67% compared to the previous year.
Employees
10
Change (1Y)
-2
Growth (1Y)
-16.67%
Revenue / Employee
$49,300
Profits / Employee
-$3,414,900
Market Cap
46.53M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SHL Telemedicine | 583 |
HOOKIPA Pharma | 179 |
Accelerate Diagnostics | 134 |
Vicarious Surgical | 131 |
Carisma Therapeutics | 107 |
CollPlant Biotechnologies | 75 |
CalciMedica | 12 |
Serina Therapeutics | 11 |
VYNE News
- 2 months ago - VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewsWire
- 5 months ago - VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 - GlobeNewsWire
- 6 months ago - VYNE Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 8 months ago - VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire